November 7, 2024
Headlines

Medicine

Monument Therapeutics Secures £1M Investment to Advance Schizophrenia Treatment Program

Editor05 mins

Monument Therapeutics, a leader in precision neuroscience, has announced a significant £1 million equity investment from the Forster Foundation, a charitable organization. This new funding builds on previous equity and non-dilutive investments disclosed in April 2024, and will support the clinical development of MT1988, an innovative treatment targeting cognitive symptoms of schizophrenia. Cognitive impairments associated…

Read More

MediWound Secures €16.25 Million in Funding to Accelerate Development of EscharEx® for Diabetic Foot Ulcers

Editor03 mins

MediWound Ltd. (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced a major funding milestone through the European Innovation Council (EIC) Accelerator program. The company has been awarded €16.25 million to propel the clinical development of EscharEx®, a groundbreaking biologic aimed at treating diabetic foot ulcers (DFUs). The EIC’s decision to support…

Read More

AI Injects Precision into Pharma Manufacturing: Modicus Prime Secures $3.5 Million

Editor03 mins

Good news for the pharmaceutical industry! Modicus Prime, a Texas-based innovator, has secured $3.5 million in Series A funding to revolutionize drug manufacturing with their AI-powered quality control solution, mpVision. This investment, led by Silverton Partners, empowers Modicus Prime to tackle a persistent challenge – ensuring consistent quality and eliminating costly errors during production. Traditionally,…

Read More

NanoPass Technologies Secures $4 Million Investment to Revolutionize Intradermal Delivery

Editor04 mins

Nanopass Technologies, a pioneer in intradermal delivery solutions, has secured a significant $4 million investment from lead investor Awz Ventures, as part of a $6 million funding round. This marks a major milestone for NanoPass, solidifying their position as a frontrunner in the development of safe, precise, and efficient drug delivery methods. The investment fuels…

Read More

Iktos Expands AI-Driven Drug Discovery Capabilities with Acquisition of Synsight

Editor04 mins

Iktos, a pioneering leader in AI and Robotics for drug design, has announced its acquisition of Synsight, a renowned French biotech company specializing in AI-driven drug discovery targeting protein-protein (PPI) and RNA-protein (RPI) interactions. This strategic merger bolsters Iktos’ comprehensive AI-based drug discovery platform, integrating Synsight’s advanced technology to enhance biological testing capabilities crucial for…

Read More
Dr. Mark Lee, M.D., Ph.D., N-Power Medicine

N-Power Medicine Raises $72M in Series B Funding to Advance Oncology Clinical Trials Platform

Editor05 mins

N-Power Medicine, a trailblazer in redefining the clinical trial landscape, has announced a significant milestone with the closure of its Series B funding round, securing $72 million in total funding. Led by the Merck Global Health Innovation Fund, alongside a prominent U.S.-based healthcare investor, this funding infusion marks a pivotal moment for N-Power Medicine as…

Read More

NeOnc Technologies Secures $18.5 Million to Propel Breakthrough Brain Cancer Therapies Through Phase II Trials

Editor05 mins

NeOnc Technologies Holdings, Inc., a forefront player in clinical-stage biotechnology, has successfully concluded an $18.5 million financing round aimed at advancing its innovative approach to treating brain cancer. This funding milestone includes new equity investment and debt conversions, reflecting a substantial increase in NeOnc’s valuation and reinforcing its commitment to pioneering neurological therapeutics. The financing…

Read More

DiaMedica Therapeutics Secures $11.8 Million Investment to Advance Breakthrough Treatments

Editor04 mins

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a pioneering biopharmaceutical firm renowned for its innovative approach to severe ischemic diseases, has announced a significant milestone today. The company successfully finalized agreements for a private placement offering, securing $11.8 million in gross proceeds from accredited investors. This strategic funding round underscores DiaMedica’s commitment to advancing clinical and product…

Read More

Formation Bio Secures $372 Million Series D Funding to Propel AI-Driven Drug Development

Editor07 mins

Formation Bio, a pioneering force at the intersection of technology and pharmaceuticals, has announced a landmark achievement with the closure of a $372 million Series D financing round. This funding round was led by prominent investors including a16z and Sanofi, with continued support from existing backers such as Sequoia, Thrive, Emerson Collective, and Lachy Groom,…

Read More

UroMems Raises $47 Million in Series C Funding to Advance Groundbreaking Treatment for Stress Urinary Incontinence

Editor05 mins

UroMems, a pioneering global company specializing in mechatronics technology for treating stress urinary incontinence (SUI), has secured $47 million in its Series C financing round, marking a record fundraising achievement for the company. This capital infusion will propel pivotal clinical trials of their groundbreaking UroActive™ System, the world’s first smart automated artificial urinary sphincter (AUS)…

Read More